Evolve Private Wealth LLC Makes New $2.55 Million Investment in Gilead Sciences, Inc. $GILD

Posted by Geri Gentry on Aug 23rd, 2026

Gilead Sciences logo Evolve Private Wealth LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 20,202 shares of the biopharmaceutical company’s stock, valued at approximately $2,552,000.

Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC increased its position in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new position in shares of Gilead Sciences during the 4th quarter valued at about $215,000. Sivia Capital Partners LLC grew its stake in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares during the period. Ieq Capital LLC grew its stake in shares of Gilead Sciences by 12.0% during the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after acquiring an additional 12,705 shares during the period. Finally, Diversify Advisory Services LLC increased its holdings in Gilead Sciences by 18.6% in the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 674 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the transaction, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at $22,918,780.56. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 87,000 shares of company stock worth $11,562,960 in the last three months. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Up 1.9%

Shares of GILD opened at $146.12 on Friday. The business’s 50 day moving average is $131.97 and its 200 day moving average is $136.59. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The company has a market capitalization of $181.18 billion, a PE ratio of -54.73 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the prior year, the company posted $2.01 EPS. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is -122.85%.

Analyst Ratings Changes

A number of research firms have commented on GILD. Rothschild & Co Redburn decreased their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. HSBC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Wednesday, August 5th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Finally, Barclays lowered their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Read Our Latest Report on Gilead Sciences

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.